

Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe aisbl (MPE)

YEAR: 2024

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
Alexion	22.500 €	2,1%
Amgen	30.000 €	2,8%
Astra Zeneca	2.500 €	0,2%
BindingSite	11.481 €	1,1%
Bristol Myers Squibb	137.000 €	12,6%
GlaxoSmithKline	147.191 €	13,6%
Janssen	117.008 €	10,8%
Kite, a Gilead Company	48.833 €	4,5%
Menarini Stemline	51.950 €	4,8%
Oncopeptides	15.000 €	1,4%
Pfizer	99.151 €	9,1%
Prothena	30.267 €	2,8%
Regeneron	107.500 €	9,9%

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Roche	31.010 €	2,9%
Sandoz	1.284 €	0,1%
Sanofi	95.919 €	8,8%
Servier	1.155 €	0,1%
Takeda	56.930 €	5,2%
Subtotal:	1.006.677 €	92,8%

MPE Non-industry related income – Public Funding		
Source of funding³	Amount of income	% of overall organisation's income
HE ASCERTAIN	24.286 €	2,2%
HE CERTAINTY	12.977 €	1,2%
IMI HARMONY	68 €	0,0%
IMI SISAQoL	20.511 €	1,9%
ROR2	6.000 €	0,6%
T2Evolve	304 €	0,0%
Subtotal:	64.146 €	5,9%

³ E.g. membership fees, donations.

MPE Non-industry related income		
EHA	705 €	0,1%
EPAI gUG	10.223 €	0,9%
ESMO	513 €	0,0%
Other Non-Industry (various)	2.841 €	0,3%
Subtotal:	14.281 €	1,3%
TOTAL⁴:	1.085.104 €	100,0%

Information required to be included on organisation's website	Please include links below:
Funding sources:	https://www.mpeurope.org/about-mpe/funding-sources/
Overall proportion of industry and non-industry:	Industry: 92,8%; Non-Industry incl. Public Funding: 7,2%
Percentage of the highest contribution from a single company:	13,6% of overall organizations income

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf